The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
NCT ID: NCT04171323
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1305 participants
INTERVENTIONAL
2020-03-03
2028-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Active Mind Study
NCT03289546
Elucidating the Necessary Active Components of Training
NCT05366023
Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia
NCT06149013
Mindfulness for Cognition in Early-stage Alzheimer's Disease
NCT06792877
Effects of Mental Stimulation in Patients With Mild Cognitive Impairment
NCT01212692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the U01 phase, the primary objective was to design and pilot-test an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). The longitudinal endpoint goal is delaying dementia onset.
The secondary objectives of the U01 phase were:
\- To pilot test a plan to recruit and enroll under-represented minorities with the goal of obtaining a sample representative of the USF population in race and ethnicity.
In the current R01 phase:
The primary objective is to conduct an adaptive, randomized clinical trial (RCT) of cognitive training (CT) combinations aimed to enhance performance of instrumental activities of daily living (IADL) among persons with mild cognitive impairment (MCI). The longitudinal endpoint goal is reducing dementia incidence.
Design: The design is an adaptive randomized trial to identify the best combination of CT exercises to improve IADL function and thereby delay dementia onset among persons with MCI. Four arms of CT will be compared to an active control condition.
Outcomes: incident dementia is the primary outcome. Secondary outcome is Everyday Function: measures include Timed Instrumental Activities of Daily Living and iFunction. A composite of performance (measured by time and accuracy) will be derived.
Interventions and Duration: Four combinations of computerized cognitive training and an active control computerized stimulation will be investigated. The five arms will be equivalent in terms of frequency and duration of each session (60 min/day, two-three days/wk, 16 weeks).
Sample size: The study team plans to enroll up to 1305 participants. Individuals with a clinical diagnosis of MCI will be included in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTabc
Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
Cognitive Training
Participants will be completing a total of 40 computerized sessions.
Computerized Cognitive Stimulation
Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
Computerized Cognitive Stimulation
Participants will be completing a total of 40 computerized cognitive stimulation sessions.
CTa
Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
Cognitive Training
Participants will be completing a total of 40 computerized sessions.
CTab
Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
Cognitive Training
Participants will be completing a total of 40 computerized sessions.
CTac
Participants will complete computerized cognitive training. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
Cognitive Training
Participants will be completing a total of 40 computerized sessions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Training
Participants will be completing a total of 40 computerized sessions.
Computerized Cognitive Stimulation
Participants will be completing a total of 40 computerized cognitive stimulation sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Montreal Cognitive Assessment Score of 18-27 inclusive
* History of some change in cognitive function relative to established baseline and either 1) a CDR of 0.5; or 2) CDR of 0 and a clinical diagnosis of mild cognitive impairment (MCI) based on a multidisciplinary evaluation that included standardized neuropsychological testing
* If reports use of medications typically prescribed for dementia such as Namenda, Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine, or Reminyl, dose has been stable for at least 30 days
* Adequate auditory capacity to understand normal speech. No greater than moderate hearing loss evident by thresholds less than or equal to 50 dB at 1000 and 2000 Hz in at least one ear determined by an audioscope.
* Adequate visual capacity to read from a computer screen at a normal viewing distance as measured by binocular visual acuity of 20/50 or better tested with a standard near visual acuity chart
* Reports and shows adequate motor capacity to touch a computer screen or control a computer mouse.
* Wiling to complete all study activities
* Willing and capable of providing informed consent
* Ability to understand study procedures and comply with them for the length of the study
Exclusion Criteria
* Dementia diagnosis
* Clinical Dementia Rating Scale of 1 or greater
* History of large vessel stroke with significant residual motor or cognitive impairment
* History of moderate to severe traumatic brain injury with residual cognitive symptoms
* History of brain tumor
* Undergoing or plans to undergo surgery requiring anesthesia, chemotherapy, or radiation treatment in the six months following screening
* Congestive heart failure diagnosis
* Primary diagnosis of idiopathic Parkinson's disease
* Multiple sclerosis or Amyotrophic lateral sclerosis (ALS) diagnosis
* Evidence of a non-neurodegenerative neurological disorder that would interfere with the ability to carry out study activities.
* Evidence of any other unstable medical conditions that would interfere with the ability to carry out study activities or cause fluctuations in cognition (e.g., unstable diabetes, chronic obstructive pulmonary disorder dependent on oxygen)
* Geriatric Depression short scale score \>5/15. Participants with mood disorders that are treated and stable and have a GDS score \< 6/15 are not excluded.
* Any other clinically significant or unstable medical condition (e.g., ongoing alcohol dependency or drug abuse, schizophrenia, psychosis) that in the assessor's opinion would interfere with the ability to carry out study activities.
* Previous participation in 10 or more hours of a computerized cognitive intervention program in the past two years
* Previous participation in cognitive intervention research at the study site in the past 2 years
* Planning on going away or being otherwise unavailable for a period of more than three weeks in the six months following screening
* Contraindications to MRI such as pacemaker, metal implants in body, or claustrophobia
55 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
University of Minnesota
OTHER
National Institute on Aging (NIA)
NIH
Clemson University
OTHER
University of California, San Francisco
OTHER
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jerri Edwards
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerri Edwards, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California San Francisco
San Francisco, California, United States
University of Florida
Gainesville, Florida, United States
Active Mind Study
Tampa, Florida, United States
University of Minnesota
Minneapolis, Minnesota, United States
Clemson University
Greenville, South Carolina, United States
Clemson University
Seneca, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Andrew O'Shea
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WIRB® Protocol #20192632
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.